The erbB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

Annual Review of Medicine

Volumn 55, Issue , 2004, Pages 433-457

  Rowinsky, Eric K ^a,b  

^a CTRC Institute for Drug Development   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

EGFR; EKB 569; Epidermal growth factor receptor; Erlotinib CI 1033; Gefitinib; GW572016

Indexed keywords

CANERTINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MATUZUMAB; MDX 447; PANITUMUMAB; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

BONE MARROW SUPPRESSION; CANCER CELL DESTRUCTION; CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ENZYME ACTIVATION; FOLLICULITIS; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; IC 50; KIDNEY CARCINOMA; LIGAND BINDING; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS INHIBITION; MITOSIS INHIBITION; MUCOSA INFLAMMATION; NAUSEA; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY;

ANTIBODIES, MONOCLONAL; HUMANS; NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 1542329005     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.55.091902.104433     Document Type: Review

References (60)

1. Tzahar E, Pinkas-Kramarski R, Moyer JD, et al. 1997. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J. 16:4938-50
2. Cohen S, Carpenter G. 1975. Human epidermal growth factor: isolation and chemical and biological properties. Proc. Natl. Acad. Sci. USA 72:1317-21
3. Shelly M, Pinkas-Kramarski R, Guarino BC, et al. 1998. Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J. Biol. Chem. 273:10496-505
4. Derynck R. 1998. Transforming growth factor alpha. Cell 54:593-95
5. Simon MA. 2000. Receptor tyrosine kinases: specific outcomes from general signals. Cell 103:13-15
6. Walker RA. 1998. The erbB/HER type 1 tyrosine kinase receptor family. J. Pathol. 185:234-35
7. Yarden Y, Sliwkowski MX. 2001. Untangling the ErbB signaling network. Nat. Rev. Mol. Cell. Biol. 2:127-37
8. Schlessinger J. 2000. Cell signaling by receptor tyrosine kinases. Cell 103:211-25
9. Daly RJ. 1999. Take your partners, please: signal diversification by the erbB family of receptor tyrosine kinases. Growth Factors 16:255-63
10. Riese DJ II, Stern DF. 1998. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20:41-48
11. Olayioye MA, Neve RM, Lane HA, et al. 2000. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19:3159-67
12. Stern DF, Kamps MP. 1998. EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. EMBO J. 7:995-1001
13. Graus-Porta D, Beerli RR, Daly JM, et al. 1997. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16:1647-55
14. Sorkin A, Di Fiore PP, Carpenter G. 1993. The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. Oncogene 8: 3021-28
15. Riese DJ II, van Raaij TM, Plowman GD, et al. 1995. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol. Cell. Biol. 15:5770-76
16. Elenius K, Choi CJ, Paul S, et al. 1999. Characterization of a naturally-occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase. Oncogene 8:2607-15
17. Yarden Y. 2001. Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl.2):1-13
18. Shtiegman K, Yarden Y. 2003. The role of ubiquitylation in signaling by growth factors: implications to cancer. Semin. Cancer Biol. 13:29-40
19. Levkowitz G, Waterman H, Zamir E, et al. 1996. c-Cb1/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 12:3663-74
20. Chow NH, Liu HS, Lee EI, et al. 1997. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res. 17: 1293-96
21. Rowinsky EK. 2001. Targeting signal transduction. The erbB receptor family as a target for therapeutic development against cancer. Horizons in Cancer Therapeutics: From Bench to Bedside, 2:3-36. West Conshohocken, PA: Meniscus Educ. Inst.
22. Moscatello DK, Holgado-Madruga M, Emlet DR, et al. 1998. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J. Biol. Chem. 273:200-6
23. Wikstrand CJ, Hale LP, Batra SK, et al. 1995. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55:3140-48
24. Slamon DJ, Godolphin W, Jones LA, et al. 1989. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244:707-12
25. Colomer R, Shamon LA, Tsai MS, et al. 2001. Herceptin: from the bench to the clinic. Cancer Invest. 19:49-56
26. Hudziak RM, Schlessinger J, Ullrich A. 1987. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA 84: 7159-63
27. Pauletti G, Godolphin W, Press MF, et al. 1996. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13: 63-72
28. Baselga J, Albanell J, Molina MA, et al. 2002. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med. 8(Suppl.4):S19-S26
29. Arteaga C. 2002. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin. Oncol. 5(Suppl. 14):3-9
30. Mendelsohn J. 2002. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 20(Suppl. 18): 1S-13S
31. Wakeling AE. 2002. Epidermal growth factor receptor tyrosine kinase inhibitors. Curr. Opin. Pharmacol. 2:382-87
32. Arteaga CL, Moulder SL, Yakes FM. 2002. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin. Oncol. 29(Suppl. 11):4-10
33. De Bono JS, Rowinsky EK. 2002. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med. 8(Suppl. 4):S19-26
34. Fan Z, Lu Y, Wu X, et al. 1994. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J. Biol. Chem. 269: 27595-602
35. Mendelsohn J. 2000. Blockade of receptors for growth factors: an anticancer therapy: the fourth annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Clinical Award Lecture. Clin. Cancer Res. 6:747-52
36. Baselga J, Mendelsohn J. 1997. Type I receptor tyrosine kinases as targets for therapy in breast cancer. J. Mammary Gland Biol. Neoplasia 2:165-74
37. Wu X, Fan Z, Masui H, et al. 1995. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody to a human colorectal carcinoma cell line and its delay by insulin. J. Clin. Invest. 95:1897-905
38. Goldstein NI, Prewett M, Zuklys K, et al. 1993. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 53:4322-28
39. Fontanini G, De Laurentiis M, Vignati S, et al. 1988. Evaluation of epidermal growth factor-related growth factors and receptors and neoangiogenesis in completely resected stage I-IIIA non-small cell lung cancer: amphiregulin and microvessel counts are independent prognostic indicators of survival. Clin. Cancer Res. 4:241-49
40. Cohen RB. 2003. Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin. Colorectal Cancer 2:246-51
41. Ritter CA, Arteaga CL. 2003. The epidermal growth factor receptor tyrosine kinase: a promising therapeutic target in solid tumors. Semin. Oncol. 30:1(Suppl. 1):3-11
42. Arteaga CL. 2002. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7(Suppl.4):31-39
43. Yang XD, Jia XC, Corvalan JR, et al. 1999. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59:1236-43
44. Yang X, Jia X, Corvalan JR, et al. 2001. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit. Rev. Oncol. Hematol. 38:17-23
45. Rowinsky E, Schwartz G, Dutcher J, et al. 2002. ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody: phase II clinical trial in renal cell cancer. Eur. J. Cancer. 38(Suppl. 7):S57-S65
46. Figlin RA, Belldegrun AS, Crawford J, et al. 2002. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) in patients with advanced cancer: phase 1 clinical results. Proc. Am. Soc. Clin. Oncol. 21:10a (Abstr.)
47. Meropol NJ, Berlin J, Hecht JR, et al. 2003. Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 22:256 (Abstr.)
48. Pfister DG, Lipton A, Belt R, et al. 1999. A phase I trial of the epidermal growth factor receptor (EGFR)-directed bispecific antibody (BsAB) MDX-447 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 18:256 (Abstr.)
49. Levitt ML, Koty PP. 1999. Tyrosine kinase inhibitors in preclinical development. Invest. New Drugs 17:213-26
50. Fry DW. 2000. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Des. 15:3-16
51. Baselga J, Averbuch SD. 2000. ZD1839 ('Iressa') as an anticancer agent. Drugs 60(Suppl. 1):33-40
52. Albanell J, Rojo F, Averbuch S, et al. 2002. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients. Histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. 20:110-24
53. Moyer JD, Barbacci EO, Iwata KK, et al. 1997. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57:4838-48
54. Hidalgo M, Siu LL, Nemunaitis J, et al. 2001. A phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19:3267-79
55. Fry DW. 2000. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer. Anticancer Drug Des. 15:3-16
56. Xia W, Mullin MJ, Keith BR, et al. 2002. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk 1/2 and AKT pathways. Oncogene 21:6255-63
57. Greenbeiger LM, Discafani C, Wang Y-F, et al. 2000. EKB-569: a new irreversible inhibitor of EGFR tyrosine kinase for the treatment of cancer. Clin. Cancer Res. 6(Suppl.):4544s
58. Averbuch SD. 2002. Lung cancer prevention: retinoids and the epidermal growth factor receptor - a phoenix rising? Clin. Cancer Res. 1:1-3
59. Torrance CJ, Jackson PE, Montgomery E, et al. 2000. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 6:1024-28
60. Spector N, Raefsky E, Hurwiz H, et al. 2003. Safety, clinical efficacy, and biologic assessments from EGF10004, a randomized phase IB study of GW572016 for patients with metastatic carcinomas over-expressing EGFR or erbB2. Proc. Am. Soc. Clin. Oncol. 18:193a(Abstr.)